Literature DB >> 35141721

Stability of Olmesartan Medoxomil Extemporaneous Suspensions.

Prapanna Bhattarai1, Timothy McPherson1, Marcelo Nieto1, William M Kolling1.   

Abstract

Background: Olmesartan medoxomil (OLM) is only available in the United States as tablets. The United States Pharmacopoeia (USP) has placed OLM on its priority list of preparations that require stability data to support practitioner compounding. Objective: The purpose of the study was to develop a stability-indicating assay and then determine the beyond-use date (BUD) for an extemporaneous OLM suspension.
Methods: A reverse-phase high-performance liquid chromatography (HPLC) assay was developed and validated according to guidelines for USP official compounded monographs. OLM 2 mg/mL suspensions were compounded with Ora-Sweet and Ora-Plus and stored at room temperature or in a refrigerator. Suspensions were assayed periodically over 90 days for OLM concentration and observed for physical stability. The pH was measured at the beginning and end of the study.
Results: The OLM concentration remained above 97% of the starting concentration for 90 days when stored in the refrigerator and above 94% of the starting concentration for 90 days when stored at room temperature. The suspension pH did not change and indicators of physical stability were unchanged for 90 days.
Conclusion: OLM 2 mg/mL suspensions were chemically and physically stable at room temperature and in the refrigerator for 90 days. The BUD may be set at 90 days under either storage condition.
© The Author(s) 2021.

Entities:  

Keywords:  beyond-use-date; extemporaneous; olmesartan; stability; suspension

Year:  2021        PMID: 35141721      PMCID: PMC8820043          DOI: 10.1177/87551225211051756

Source DB:  PubMed          Journal:  J Pharm Technol        ISSN: 1549-4810


  8 in total

1.  Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets.

Authors:  Lisiane Bajerski; Rochele Cassanta Rossi; Carolina Lupi Dias; Ana Maria Bergold; Pedro Eduardo Fröehlich
Journal:  AAPS PharmSciTech       Date:  2010-04-07       Impact factor: 3.246

2.  Development and Validation of a Stability-Indicating Liquid Chromatographic Method for Estimating Olmesartan Medoxomil Using Quality by Design.

Authors:  Sarwar Beg; Gajanand Sharma; O P Katare; Shikha Lohan; Bhupinder Singh
Journal:  J Chromatogr Sci       Date:  2015-01-12       Impact factor: 1.618

3.  Difficulties swallowing solid oral dosage forms in a general practice population: prevalence, causes, and relationship to dosage forms.

Authors:  Julia T Schiele; Renate Quinzler; Hans-Dieter Klimm; Markus G Pruszydlo; Walter E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2012-09-29       Impact factor: 2.953

4.  RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions.

Authors:  Ritesh N Sharma; Shyam S Pancholi
Journal:  Acta Pharm       Date:  2010-03       Impact factor: 2.230

Review 5.  A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker.

Authors:  David E Mire; Tonous N Silfani; Michael K Pugsley
Journal:  J Cardiovasc Pharmacol       Date:  2005-11       Impact factor: 3.105

6.  Underdiagnosis of hypertension in children and adolescents.

Authors:  Matthew L Hansen; Paul W Gunn; David C Kaelber
Journal:  JAMA       Date:  2007-08-22       Impact factor: 56.272

Review 7.  The global epidemiology of hypertension.

Authors:  Katherine T Mills; Andrei Stefanescu; Jiang He
Journal:  Nat Rev Nephrol       Date:  2020-02-05       Impact factor: 28.314

8.  Preparation and Characterization of Self-Microemulsifying Drug Delivery System of Olmesartan Medoxomil for Bioavailability Improvement.

Authors:  Shailesh T Prajapati; Harsh A Joshi; Chhaganbhai N Patel
Journal:  J Pharm (Cairo)       Date:  2012-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.